http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#Head http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00388 http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association http://www.w3.org/2000/01/rdf-schema#label "Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension, or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.1 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. [ 4.2 Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients [See Dosage and Administration section" http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00388 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#provenance http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#pubinfo http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig http://purl.org/nanopub/x/hasSignature CeVfrWlunG5MuE0AHRsdOCenuiibn2U8HgL48VA+FKnlAeC0uC9xqskTjEhrPwaRlnTRgF201nRV6oMPOW1rI15fJgbIFC7bT98K2ngbhUqwx6ebjQ+FE6T7pYjXBSRh7lyBkRCuD8pADJKt7M/mD9cPEa6WC7iBC2XPRCOwuAw= http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://purl.org/dc/terms/created 2021-08-25T13:33:11.099+02:00 http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAQxql8Xc2GOZ1nI99ut1OYiUjuZ6RbblMLH_Ve3iFuVg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY